The new generation of Alzheimer's disease drugs—the first proven to change the course of the disease—typically extend ...

On this episode of Aging Untold, we’ll discuss wandering and the concerns many loved ones and caregivers have concerning ...

A new Gerontological Society of America (GSA) report summarizes survey findings on the readiness of the primary care workforce to adopt digital ...

The chair of the independent commission on social care recommends introducing a full-time dementia tsar, and new fast-track ...

When specialized cells called tanycytes stop working, disease-causing tau proteins build up in the brain. A group of specialized cells play a crucial part in clearing toxic proteins from inside the ...

The impact of neflamapimod on neurofilament light levels will be examined in a study of approximately 35 patients with ALS, ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

In the United States, more than 6 million individuals are living with Alzheimer’s disease, and there are about 11 million unpaid caregivers supporting them. Around the world, the disease impacts an ...

A recent study shows that accessible blood tests can accurately identify Alzheimer’s disease. When combined with standard cognitive assessments, these tools offer a reliable diagnostic approach for ...

Alzheimer's-related brain changes progressed up to 20 times faster in women who also had abnormal levels of a Parkinson's-related protein, according to a Mayo Clinic study published in JAMA Network ...

The conversation around high blood pressure could not be more urgent, especially in the African-American community. According ...

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements ...